Meta-Analysis
doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysisAffiliations
AffiliationsItem in Clipboard
Meta-Analysis
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysisJing Yang et al. Int J Infect Dis. 2020 May.
doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12. AffiliationsItem in Clipboard
AbstractBackground: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries.
Aims: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients.
Methods: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models.
Results: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively.
Conclusion: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
Keywords: COVID-19; Clinical characteristics; Comorbidities; Epidemiology; Meta-analysis; SARS-CoV-2.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FiguresFigure 1
Flow diagram of the number…
Figure 1
Flow diagram of the number of studies screened and included in the meta-analysis.
Figure 1Flow diagram of the number of studies screened and included in the meta-analysis.
Figure 2
Meta-analysis of the comorbidities in…
Figure 2
Meta-analysis of the comorbidities in COVID-19 cases. A, B, C, D represent proportions…
Figure 2Meta-analysis of the comorbidities in COVID-19 cases. A, B, C, D represent proportions of hypertension, diabetes, respiratory system disease, and cardiovascular disease.
Figure 3
The risk of comorbidities in…
Figure 3
The risk of comorbidities in severe patients compared to non-severe patients. (A) hypertension,…
Figure 3The risk of comorbidities in severe patients compared to non-severe patients. (A) hypertension, (B) diabetes, (C) respiratory system disease, (D) cardiovascular disease.
Comment inPal R, Bhadada SK. Pal R, et al. Postgrad Med J. 2020 Jul;96(1137):429-430. doi: 10.1136/postgradmedj-2020-137742. Epub 2020 Mar 30. Postgrad Med J. 2020. PMID: 32234837 Free PMC article. No abstract available.
Liu Y, Wu S, Qin M, Jiang W, Liu X. Liu Y, et al. J Am Heart Assoc. 2020 Sep;9(17):e016812. doi: 10.1161/JAHA.120.016812. Epub 2020 Jul 15. J Am Heart Assoc. 2020. PMID: 32673529 Free PMC article. Review.
Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, He L, Jiang Q, Wang Z, Fu W, Li Z, Lu Q, Chen Z, Ding S. Xiong S, et al. BMC Infect Dis. 2020 Oct 22;20(1):787. doi: 10.1186/s12879-020-05452-2. BMC Infect Dis. 2020. PMID: 33092539 Free PMC article.
Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, Demertzis Z, Hanna Z, Failla A, Dagher C, Chaudhry Z, Vahia A, Abreu Lanfranco O, Ramesh M, Zervos MJ, Alangaden G, Miller J, Brar I. Suleyman G, et al. JAMA Netw Open. 2020 Jun 1;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270. JAMA Netw Open. 2020. PMID: 32543702 Free PMC article. Review.
Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, Wu Y, Sun L, Xu Y. Hu Y, et al. J Clin Virol. 2020 Jun;127:104371. doi: 10.1016/j.jcv.2020.104371. Epub 2020 Apr 14. J Clin Virol. 2020. PMID: 32315817 Free PMC article.
Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Sun P, et al. J Med Virol. 2020 Jun;92(6):612-617. doi: 10.1002/jmv.25735. Epub 2020 Mar 11. J Med Virol. 2020. PMID: 32108351 Free PMC article.
Vo AD, La J, Wu JT, Strymish JM, Ronan M, Brophy M, Do NV, Branch-Elliman W, Fillmore NR, Monach PA. Vo AD, et al. JAMA Netw Open. 2022 Oct 3;5(10):e2240037. doi: 10.1001/jamanetworkopen.2022.40037. JAMA Netw Open. 2022. PMID: 36264571 Free PMC article.
Koduri G, Gokaraju S, Darda M, Warrier V, Duta I, Hayes F, Sayed IE, Noeman-Ahmed Y. Koduri G, et al. Eur Geriatr Med. 2021 Oct;12(5):1065-1073. doi: 10.1007/s41999-021-00508-1. Epub 2021 Jun 4. Eur Geriatr Med. 2021. PMID: 34086193 Free PMC article.
Ciornei RT. Ciornei RT. Front Immunol. 2020 Jul 14;11:1762. doi: 10.3389/fimmu.2020.01762. eCollection 2020. Front Immunol. 2020. PMID: 32760408 Free PMC article. No abstract available.
Banerjee M, Gupta S, Sharma P, Shekhawat J, Gauba K. Banerjee M, et al. Indian J Clin Biochem. 2020 Oct;35(4):410-417. doi: 10.1007/s12291-020-00909-2. Epub 2020 Jul 10. Indian J Clin Biochem. 2020. PMID: 32837031 Free PMC article. Review.
Manzanedo RD, Manning P. Manzanedo RD, et al. Sci Total Environ. 2020 Nov 10;742:140563. doi: 10.1016/j.scitotenv.2020.140563. Epub 2020 Jun 27. Sci Total Environ. 2020. PMID: 32619845 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3